Blood vessel protein
Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack
Home / Health News / 2008 / March 2008 / March 17, 2008
Blood vessel protein opens path to treat macular degeneration, diabetic retinopathy

Top News

Karnataka High Court orders Ramoji Rao to appear in Ballari Court

BJP, Left and JD (S) condemn bomb blasts in Bangalore

No one has power to dissolve assemblies: Pak PM

Speed 2: Cruise Control voted as Worst Ever Sequel

Japan-US alliance should be expanded by including India, Australia

Kalmadi hopeful of India wining medals in tennis, boxing and shooting

Hubble finds largest sample of very distant galaxies seen to date

Adult stem cells finding provides foundation for brain injury cure

Blood vessel protein opens path to treat macular degeneration, diabetic retinopathy

Researchers at the University of Utah School of Medicine and several other institutions have revealed that two major eye diseases and leading causes of blindness - age-related macular degeneration (AMD) and diabetic retinopathy - can be reversed or even prevented by drugs that activate a protein found in blood vessel cells.

London, Mar 17 : Researchers at the University of Utah School of Medicine and several other institutions have revealed that two major eye diseases and leading causes of blindness - age-related macular degeneration (AMD) and diabetic retinopathy - can be reversed or even prevented by drugs that activate a protein found in blood vessel cells.

In the study, Dean Y. Li, M.D., Ph.D., senior author of the study and colleagues found that damage from both diseases was prevented and even reversed when the protein, Robo4, was activated in mice models that simulate age-related macular degeneration and diabetic retinopathy.

The researchers found that Robo4 treated and prevented the diseases by inhibiting abnormal blood vessel growth and by stabilizing blood vessels to prevent leakage, the two primary factors in both age-related macular degeneration (AMD) and diabetic retinopathy.

"This discovery has significant implications for developing drugs that activate Robo4 to treat AMD and diabetic retinopathy," Nature quoted Kang Zhang, M.D., Ph.D., associate professor of ophthalmology and visual sciences at the University of Utah's John A. Moran Eye Center and an investigator with the University's Program in Human Molecular Biology and Genetics, as saying.

Li and Zhang collaborated on the study, using the same animal models of AMD and diabetic retinopathy that are required for drug development.

The collaboration between Li and Zhang means the time required to test the approach in people could be shortened, perhaps by years.

Nonetheless, both the researchers warned that getting new drugs to market still would take a number of years.

Robo4 can be seen only in cells in the interior surface of blood vessels and is activated by a protein called Slit.

After being activated, the protein initiates a chain of biochemical events to stabilize blood vessels and prevent uncontrolled growth.

The study is published on March 16 in Nature Medicine online.

ANI

July 25, 2008

July 24, 2008

July 23, 2008

July 22, 2008

July 21, 2008

July 20, 2008